• San Diego-based Tryp Therapeutics is developing new drug candidates with the aim of treating medical conditions that currently have limited effective therapy
• Tryp has solidified an agreement with the University of Michigan’s Chronic Pain & Fatigue Research Center and the Center for Consciousness Science to test synthetic psychedelic drug candidate TRP-8803 to advance its use in upcoming clinical trials
• The Company has also established an agreement with the University of Florida to test its lead drug candidate — TRP-8802 — for certain eating disorders
• Psychedelics are beginning to gain new respect and attention for addressing select neurological conditions as scientists, legislators and former drug opponents re-evaluate their views on the substances’ potential benefits

As a growing number of investigational scientists evaluate the potential of psychedelics to open a new field of medicinal solutions, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is moving forward with its mission to treat otherwise underserved chronic pain and eating disorder indications using its lead drug candidate TRP-8802, a synthetic psilocybin formulation.

On July 7, the Company announced that an additional psilocybin-based formulation, TRP-8803, will be part of a series of upcoming bridging studies at the University of Michigan’s Chronic Pain & Fatigue Research Center and the Center for Consciousness Science in the Department of Anesthesiology. 

The aim of comparing TRP-8803 with conventional oral formulations of synthetic psilocybin in the studies is to “explore 1) the relationship between a psilocybin-induced increase in neurophysiological complexity and indices of pain in a preclinical model for chronic central pain, 2) the effect of alternative delivery methods of psilocybin on indices of pain and insular glutamate/GABA, and 3) PK analysis for blood samples from both oral and novel methods of delivery of psilocybin,” according to the announcement (https://ibn.fm/XL1B0).

Tryp also entered an agreement with the University of Florida to conduct a Phase 2a clinical trial for treating certain eating disorders using TRP-8802, which is being forged in partnership with psychedelic therapy educational platform Fluence (https://ibn.fm/l3ERb) and Contract Research Organization (“CRO”) Clinlogix (https://ibn.fm/UGbSG). 

The TRP-8803 studies at the University of Michigan aim to similarly advance the drug candidate for neurological-based maladies toward future Phase 2b clinical trials. 

George Mashour, M.D., Ph.D., will advise the Company on its initial clinical study design for TRP-8803. Dr. Mashour is recognized globally as an expert on the neurobiology of consciousness and general anesthesia and he currently serves as the principal investigator for several NIH grants in the field of neuroscience, academic anesthesiology and translational science, according to the announcement. 

“I have been impressed with the scientific rigor and innovation from the team at Tryp as well as their collaborative spirit. I look forward to making great strides together toward addressing unmet patient needs in a wide range of indications,” Mashour stated. 

The University of Michigan has become a hotbed for medicinal psychedelics advocacy, and they believe society has reached a watershed moment for the substances’ acceptance for medical treatments. The Michigan Psychedelic Society was established in 2017 to promote education and harm reduction, and the U-M Student Association for Psychedelic Studies (“SAPS”) was launched the same year, building a steady increase in awareness (https://ibn.fm/nw2P1).

The publishing wing of Harvard’s medical school likewise carried an article last month that noted, “Recently, psychedelic drugs have once again taken popular culture by storm. From the psychedelic startup companies newly forming on Wall Street to a recent New York Times article that claims ‘psychedelic drugs are closer to medicinal use ’ it seems that there is a renewed media and medical interest in acid (‘LSD’), mushrooms (psilocybin), ecstasy (‘MDMA’), ayahuasca, DMT (dimethyltryptamine), and ketamine” (https://ibn.fm/posm6).

For more information on Tryp Therapeutics, visit the company’s website at www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF  

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.